Analyst Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals and keeping the price target at $3.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Hold rating due to a combination of factors affecting Inovio Pharmaceuticals. The company recently reported a higher-than-expected net loss for the third quarter of 2025, primarily due to changes in the fair value of warrant liabilities. Despite this, Inovio has made progress with its INO-3107 treatment for recurrent respiratory papillomatosis, having completed its Biologics License Application submission under the FDA’s accelerated approval program. However, acceptance of this application is not expected until the end of 2025, with a potential market launch in mid-2026, contingent on approval.
Additionally, while promising long-term efficacy data for INO-3107 has been published, indicating significant clinical benefits, the company still faces financial challenges. With a cash runway extending only to the third quarter of 2026, Inovio may need to secure additional funding within the next year to sustain its operations. These financial uncertainties, coupled with the pending regulatory milestones, contribute to the Hold rating as the company navigates through these pivotal stages.
In another report released on November 11, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $2.00 price target.